Office of Diversion Control, US Department of Justice, Drug Enforcement Administration

ABOUT US > What's New

What's New

July

Mikhayl Soliman, M.D.; Decision and Order (July 22, 2016)

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016 (July 22, 2016)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017 (July 22, 2016)

Nicholas J. Nardacci, M.D.; Decision and Order (July 21, 2016)

Turning Tide, Inc. Decision and Order; Procedural History (July 21, 2016)

James Dustin Chaney, D.O.; Decision and Order (July 21, 2016)

Cambrex Charles City (July 19, 2016)

Rhodes Technologies (July 19, 2016)

Electronic Filing of Certain Import/Export Data Relating to Controlled Substances and Listed Chemicals: Announcement of the Partner Government Agency Message Set/Document Image System Test and Request for Participants (July 15, 2016)

Janssen Pharmaceutical, Inc. (July 13, 2016)

Noramco, Inc. (July 13, 2016)

Prianglam Brooks, N.P.; Decision and Order (July 6, 2016)


June

60-Day Notice (Extension): U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222 (June 30, 2016)

60-Day Notice (Extension): Import/Export Declaration for List I and List II Chemicals, DEA Forms 486, 486A (June 13, 2016)

Controlled Substances Import/Export Declaration DEA Form 236 (June 13, 2016)

Application for Permit To Export Controlled Substances, Application for Permit To Export Controlled Substances for Subsequent Re-export, DEA Forms 161, 161R (June 13, 2016)

Sigma Aldrich Research Biochemicals, Inc. (June 13, 2016)


May

What changes have been made to the "Mailing Address" portion of the DEA Form 222?

Rhodes Technologies (May 31, 2016)

Wildlife Laboratories, Inc. (May 31, 2016)

Order With Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (May 20, 2016)

Mallinckrodt, LLC (May 20, 2016)

American Radiolabeled Chemicals (May 20, 2016)

Pharmacore, Inc. (May 20, 2016)

Superior Pharmacy I and Superior Pharmacy II; Decision and Order (May 18, 2016)

Siegfried USA, LLC (May 16, 2016)

Organix, Inc. (May 16, 2016)

Johnson Matthey Pharmaceutical Materials, Inc. (May 16, 2016)

AMRI Rensselaer, Inc. (May 16, 2016)

Johnson Matthey, Inc. (May 16, 2016)

Interim Final Rule: Placement of Brivaracetam Into Schedule V (May 12, 2016)

Final Order: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl Into Schedule I (May 12, 2016)

Final Rule: Placement of UR-144, XLR11, and AKB48 into Schedule I (May 11, 2016)

Myoderm (May 6, 2016)

Sharp Clinical Services, Inc. (May 6, 2016)

Almac Clinical Services Incorp (ACSI) (May 6, 2016)

Noramco, Inc. (May 6, 2016)

Noramco, Inc. (May 6, 2016)


April

Abolghasem Rezaei, M.D.; Decision and Order (April 28, 2016)

Ibem R. Borges, M.D.; Decision and Order (April 21, 2016)

Research Triangle Institute (April 18, 2016)

Johnson Matthey, Inc. (April 18, 2016)

Meridian Medical Technologies (April 18, 2016)

Cody Laboratories, Inc. (April 18, 2016)

30-Day Notice (Extension): Reporting and Recordkeeping for Digital Certificates (April 15, 2016)

30-Day Notice (Extension): Report of Mail Order Transactions (April 15, 2016)

Mylan Technologies, Inc. (April 15, 2016)

Final Order: Placement of AH-7921 Into Schedule I (April 14, 2016)

Rezik A. Saqer, M.D.; Decision and Order (April 14, 2016)

Patheon API Manufacturing, Inc. (April 14, 2016)

Stepan Company (April 14, 2016)

Navinta, LLC (April 7, 2016)

Stepan Company (April 7, 2016)

Fisher Clinical Services, Inc. (April 7, 2016)

Mylan Pharmaceuticals, Inc. (April 7, 2016)

VHG Labs DBA LGC Standards Warehouse (April 7, 2016)


March

Halo Pharmaceutical, Inc.; Correction (March 31, 2016)

Avi Weisfogel, D.D.S.; Decision and Order (March 30, 2016)

Exempt Chemical Preparations Under the Controlled Substances Act; Notice (March 25, 2016)

30-Day Notice (Extension): Renewal Application for Registration Under Domestic Chemical Diversion Control Act of 1993; DEA Forms 510, 510A (March 25, 2016)

Notice of Intent: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl Into Schedule I (March 23, 2016)

Meda Pharmaceuticals, Inc. (March 23, 2016)

Pharmacore (March 23, 2016)

R & D Systems, Inc. (March 23, 2016)

Mallinckrodt LLC (March 23, 2016)

Noramco, Inc. (March 23, 2016)

Cerilliant Corporation (March 23, 2016)

Siemens Healthcare Diagnostics, Inc. (March 23, 2016)

Siegfried USA, LLC (March 23, 2016)

Patheon Pharmaceuticals, Inc. (March 23, 2016)

Chattem Chemicals, Inc. (March 23, 2016)

Cerilliant Corporation (March 23, 2016)

Halo Pharmaceutical, Inc. (March 23, 2016)

Cody Laboratories, Inc. (March 23, 2016)

Halo Pharmaceutical, Inc. (March 23, 2016)

Cambrex Charles City (March 23, 2016)

30-Day Notice (Extension): Annual Reporting for Manufacturers of Listed Chemicals (March 22, 2016)

Proposed Rule: Placement of UR-144, XLR11, and AKB48 Into Schedule I; Correction (March 22, 2016)

Kristen Lee Raines, A.P.R.N.; Decision and Order (March 18, 2016)

Cambrex Charles City (March 18, 2016)

30-Day Notice (Extension): Application for Procurement Quota for a Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine, DEA Form 250 (March 15, 2016)

30-Day Notice (Extension): Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine DEA Form 189 (March 15, 2016)

Proposed Rule: Placement of 10 Synthetic Cathinones Into Schedule I (March 4, 2016)

Final Order: Extension of Temporary Placement of 10 Synthetic Cathinones in Schedule I of the Controlled Substances Act (March 4, 2016)


February

Removal of Exemption From Registration for Persons Authorized Under U.S. Nuclear Regulatory Commission or Agreement (February 26, 2016)

Cayman Chemical Company (February 24, 2016)

Janssen Pharmaceutical, Inc. (February 24, 2016)

Insys Therapeutics, Inc. (February 24, 2016)

Cedarburg Pharmaceuticals, Inc. (February 24, 2016)

Chemtos, LLC (February 24, 2016)

Cedarburg Pharmaceuticals, Inc. (February 18, 2016)

Hatem M. Ataya, M.D.; Decision and Order; Introduction and Procedural History (February 18, 2016)

Arvinder Singh, M.D.; Decision and Order (February 18, 2016)

Catalent Pharma Solutions, LLC (February 18, 2016)

Sigma Aldrich International GMBH-Sigma Aldrich Co. LLC (February 18, 2016)

Mallinckrodt, LLC (February 18, 2016)

Euticals, Inc. (February 18, 2016)

Noramco, Inc. (February 12, 2016)

60-Day Notice (Extension): Report of Mail Order Transactions (February 9, 2016)

Final Rule: Table of Excluded Nonnarcotic Products: Vicks® VapoInhaler® (February 8, 2016)

Final Rule: Table of Excluded Nonnarcotic Products: Nasal Decongestant Inhaler/Vapor Inhaler (February 8, 2016)

Proposed Rule: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I (February 5, 2016)

Final Order: Temporary Placement of the Synthetic Cannabinoid MAB-CHMINACA Into Schedule I (February 5, 2016)

Final Order: Extension of Temporary Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule I of the Controlled Substances Act (February 5, 2016)

Louis Watson, M.D.; Decision and Order (February 4, 2016)

David W. Bailey, M.D.; Decision and Order (February 4, 2016)

Kenneth H. Bull, M.D.; Decision and Order (February 4, 2016)

Pharmacore, Inc. (February 4, 2016)

Emergency Disaster Relief
Got Drugs? Turn in your unused or expired medication for safe disposal here.
Alert! Extortion Scam

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Office of Diversion Control  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539